Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses

Parnassus Investments' Q2 2026 investor letter sheds light on the challenges Boston Scientific Corporation (NYSE:BSX) faced. Despite the fund's overall strong performance, Boston Scientific's electrophysiology franchise and Watchman heart implant struggled due to increased competition and inconsistent clinical trial outcomes. Consequently, Parnassus Core Equity Fund exited the stock during the quarter.

The company's shares closed at around $51.42 on August 13, 2026, with a market value of approximately $74.91 billion. While Boston Scientific is not among the fund's top 40 most favored stocks for 2026, 106 hedge funds held the company at the end of Q1 2026, compared to 110 in the prior quarter. Parnassus Investments remains optimistic about AI-driven opportunities but acknowledges the potential of other high-value stocks.